Rui Kang

Engineering microRNAs as multimodal cancer therapeutics

Resistance to systemic therapy remains a major challenge in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved outcomes for patients with EGFR-mutant tumors, but acquired resistance is common and can arise t...